Publications by authors named "Jiazhuo Wu"
Article Synopsis
- Natural killer/T cell lymphoma (NKTCL) is highly aggressive, and patients with relapsed/refractory cases have poor outcomes, with ongoing research focusing on the role of Epstein-Barr virus (EBV) in this condition.
- The study found that LMP1, a protein associated with EBV, enhances NKTCL cell growth and survival by promoting aerobic glycolysis, which involves increased glucose uptake and lactate production, ultimately leading to reduced sensitivity to conventional treatments like gemcitabine.
- LMP1 affects the clinical progression of NKTCL, with higher levels correlating to worse outcomes, and its mechanism involves engaging the noncanonical NF-κB pathway, suggesting potential targets for new treatments.
Background: Natural killer/T cell lymphoma (NKTCL) is an aggressive lymphoma with a poor prognosis. Chimeric antigen receptor-transduced T (CAR-T) cell therapy has become a promising immunotherapeutic strategy against haematologic malignancies.
Methods: In this study, four CAR-T cell lines (CD38-CAR, LMP1-CAR, CD38-LMP1 tandem CAR 1 and CD38-LMP1 tandem CAR 2) were generated.
The treatment of natural killer/T-cell lymphoma (NKTCL) presents an onerous challenge, and a search for new therapeutic targets is urgently needed. Poly ADP-ribose polymerase inhibitors (PARPi) were initially used to treat breast and ovarian cancers with BRCA1/2 mutations. Their excellent antitumor efficacy led to a series of clinical trials conducted in other malignancies.
View Article and Find Full Text PDFBackground: PARP inhibitor (PARPi), as a kind of DNA damage repair inhibitor, has been shown to be effective in various solid tumors and hematologic malignancies. Natural killer/T cell lymphoma (NKTCL) is a highly aggressive malignancy, the treatment of which has long been a major challenge in the clinic. Here, we investigated the efficacy and mechanism of PARPi, and the therapeutic value of PARPi combined with cisplatin in NKTCL.
View Article and Find Full Text PDFBackground: Multiple myeloma (MM) is an aggressive plasma cell malignancy, causing a number of deaths worldwide every year. Chimeric antigen receptor (CAR) transduced T-cell therapy has been a promising immunotherapy against hematological malignancies.
Methods: In this study, we developed a second-generation CAR construct and generated CAR-T cells targeting CD38 molecule.